

Role of Robotic Surgery for Gynecologic Cancer

Chi-Heum Cho, M.D., PhD Keimyung University Dongsan Hospital President of ASGRS(Asian Society of Gynecologic Robotic Surgery)





Since its foundation in 2015, ASGRS is now at the center of leading the Asian gynecology and robotic surgery. Based on the spirit of challenge, we are having a future-oriented communication with consideration and solidarity.

계명대학교 동산병원





ARGC 2019 (ASIAN ROBOTIC GYNECOLOGY CONGRESS)

ASIAN ROBOTIC GYNECOLOGY CONGRESS 2019

2019. 10. 24^{THU} – **25**^{FRI} Sheraton Seoul Palace Gangnam Hotel, Seoul, Korea



ARGC 2019 (ASIAN ROBOTIC GYNECOLOGY CONGRESS)







ASIAN ROBOTIC GYNECOLOGY CONGRESS 2019

October 24 – 25 2019

















ASGRS 2022

ASGRS 2022

Asian Society for Gynecologic Robotic Surgery Congress 2022

> June 17th (Fri) - 18th (Sat), 2022 Grand Hyatt Jeju, Korea





ASGRS 2022



KEIMYUNG UNIVERSITY DONGSAN HOSPITAL

and a

ASGRS 2023 Asian Society for Gynecologic Robotic Surgery Congress 2023 June 16th (Fri) -17th (Sat), 2023 Grand Hyatt Jeju, Korea


Organization 🦂 Asian Society for Gynecologic Robotic Surgery 🕥 Society of Korean Robot Gynecologic Surgery

Asian Society for Gynecologic Robotic Surgery Congress 2022 (ASGRS 2022) Secretariat. Double You Plan E-mail. asgrs.office@gmail.com, info@doubleyou.co.kr Homepiage. www.asgrs2023.org

SKRGS



What we need in Robotic Surgery



We need to combine the power of robotics, advanced instrumentation, enhanced visualization, connectivity and data analytics into one smart, powerful, connected platform for the best of surgery outcome.



Robotic surgery in recent Gynecologic cancer

Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes



Benny Brandt ^a, Vasileios Sioulas ^a, Derman Basaran ^a, Theresa Kuhn ^a, Katherine LaVigne ^a, Ginger J. Gardner ^{a,b}, Yukio Sonoda ^{a,b}, Dennis S. Chi ^{a,b}, Kara C. Long Roche ^{a,b}, Jennifer J. Mueller ^{a,b}, Elizabeth L. Jewell ^{a,b}, Vance A. Broach ^{a,b}, Oliver Zivanovic ^{a,b}, Nadeem R. Abu-Rustum ^{a,b}, Mario M. Leitao Jr ^{a,b,*}

^a Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
^b Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY 10065, USA



B. Brandt et al. / Gynecologic Oncology 156 (2020) 591-597

Robotic surgery in recent Gynecologic cancer

Contents lists available at ScienceDirect

Gynecologic Oncology

journal homepage: www.elsevier.com/locate/ygyno



Long-term survival in obese patients after robotic or open surgery for endometrial cancer

Anna Lindfors^{a,b,*}, Heshoo Heshar^{a,b}, Claudia Adok^c, Karin Sundfeldt^{a,b}, Pernilla Dahm-Kähler^{a,b}



Gynecologic Oncology, 2020-09-01, Volume 158, Issue 3, Pages 673-680, Copyright © 2020 The Authors

Robotic surgery in recent Gynecologic cancer

Robot-assisted surgery for women with endometrial cancer: Surgical and oncologic outcomes within a Belgium gynaecological oncology group cohort

A. Kakkos ^{a, *}, C. Ver Eecke ^b, S. Ongaro ^a, K. Traen ^c, F. Peeters ^d, Ph Van Trappen ^e, A. Laenen ^f, E. Despierre ^c, E. Van Nieuwenhuysen ^b, I. Vergote ^b, F. Goffin ^a

A. Kakkos, C. Ver Eecke, S. Ongaro et al. European Journal of Surgical Oncology 47 (2021) 1117e1123




Laparoscopic vs. robotic-assisted laparoscopy in endometrial cancer staging: large retrospective singleinstitution study

Emanuele Perrone ^(a), ¹Ilaria Capasso ^(b), ^{1,2} Tina Pasciuto ^(b), ³ Alessandro Gioè ^(c), ^{1,2} Salvatore Gueli Alletti ^(b), ¹ Stefano Restaino ^(b), ¹ Giovanni Scambia ^(b), ^{1,2} Francesco Fanfani ^(b), ^{1,2}

J Gynecol Oncol. 2021 May;32(3):e45



LACC trial



KEIMYUNG UNIVERSITY DONGSAN HOSPITAL

IN ALL MARKEN ME LE MARK

MIS (Robot and LSC) vs open

Chong GO. Gynecologic Robotic Surgery | Vol 2, No. 2, September 2021

| Yea r | Nation | Design | N (Robot vs LSC vs open) | Period | Stage | Op time | Blood loss | LNs | Stay | Сх | Recurrence (Progression) | Death |
|----------|----------------|------------------------------|-----------------------------|--------------------------------|---------|----------------|---------------|-------|-------|-------|--|---|
| 200 8 | USA | Retrospectiv e, single | 27 vs 31 vs 35 | 2003- 2006 1993- 2006 | IA2-IB2 | Open, Robot | MIS | = | MIS | = | NA | NA |
| 200 9 | USA | Retrospectiv e, single | 32 vs 17 vs 14 | 2006- 2008 2002- 2006 | IA2-IB2 | = | MIS | Robot | MIS | = | NA | NA |
| 201 1 | USA, Brazil | Prospective, multi | 34 vs 31 vs 30 | 2007- 2010 | IA2-IIA | Open | MIS | NA | MIS | = | NA | NA |
| 201 1 | Norway | Prospective, single | 35 vs 7 vs 26 | 2005- 2009 2004- 2005 | IA1-IB1 | Open | Robot | Open | Robot | NA | 5 recur in only Robot | NA |
| 201 4 | Taiwan | Retrospectiv e, single | 32 vs 24 vs 44 | NA | IA-IIB | Robot | MIS | = | MIS | = | 95.8 vs 90.6 vs 90.9% | NA |
| 201 6 | USA | Retrospectiv e, single | 58 vs 49 vs 39 | 2009- 2013 | IA2-IIB | LSC | Robot | NA | Robot | Robot | 89.7 vs 89.8 vs 84.6% | 96.6 vs 95.9 vs 92.3% |
| 201 8 | Italy | Retrospectiv e, multi | 88 vs 152 vs 101 | 2001- 2016 | IB1 | = | MIS | Open | MIS | = | 5yr 89.5 vs 87.2 vs 91.3% (MIS=Open) | 5yr 88.8 vs 89.7 vs 88.7% (MIS=Open) |
| 201 8 | USA et al. | Prospective RCT | 319 (84.4% LSC) vs 312 | 2008- 2017 | IA1-IB1 | NA | NA | NA | NA | = | 3yr 91.2 vs 97.1% | 3yr 93.8 vs 99.0% |
| 201 9 | Canada | Retrospectiv e, multi | 473 (89.6% LSC) vs 485 | 2006- 2017 | IA-II | NA | NA | NA | Robot | = | 16.2 vs 8.4% (p=0.008) | 12.5 vs 5.4% (p=0.019) |
| 202 0 | EU | Retrospectiv e, multi | 291 (78.5% LSC) vs 402 | 2013- 2014 | IB1 | NA | NA | NA | NA | NA | 4.5yr 79 vs 89% (p=0.003) | 4.5yr 89 vs 97% (p=0.003) |
| 202 0 | USA | Retrospectiv e, single | 117 (90.6% Robot) vs 79 | 2007- 2017 | IA1-IB1 | NA | NA | NA | NA | MIS | 5yr 87.0 vs 86.6% (p=0.93) | 5yr 96.5 vs 87.4% (p=0.15) |



There is a curious shift in opinion seen before and after 2018

MEMORY study: MulticentEr study of MIS vs Open Radical hYsterectomy

M.M. Leitao, et al. Gynecologic Oncology 166 (2022) 417-424



Objective


- Regardless of the LACC trial's findings, there are still many unanswered questions.
 - in relation to tumor size, stage, cone biopsy only lesions, tumor containment technique improvements, individual surgeon outcomes, and preoperative assessments, among others.
- In this study, we sought to evaluate the oncologic outcomes of MIS versus OPEN radical hysterectomy for early-stage cervical cancer among a group of skilled MIS gynecologic oncologists in the US and Canada.



M.M. Leitao, et al. Gynecologic Oncology 166 (2022) 417-424

Results


Flow chart of the study population \checkmark





M.M. Leitao, et al. Gynecologic Oncology 166 (2022) 417-424

3-yr PFS / OS for the MIS and OPEN cohorts.



This study showed that an MIS compared to OPEN RH by an experienced gynecologic oncologist for cervical cancer did not appear to compromise oncologic outcomes, with similar PFS and OS.

M.M. Leitao, et al. Gynecologic Oncology 166 (2022) 417-424



1. Limitations of the MEMORY study

- Retrospective nature
 - \checkmark potential biases of selection and information
- The median follow-up time in the MIS group was also shorter than that of the OPEN group

(38.5months vs. 54.98months, respectively).

- No comment on the use of manipulators or method of colpotomy
 - The vast majority of the cases were performed with a manipulator and an intracorporeal colpotomy.
- No comment on how many cases had undergone a prior cone biopsy.



M.M. Leitao, et al. Gynecologic Oncology 166 (2022) 417-424

2. Debates in the LACC trial

- 1) The 95% CI includes the pre-specified non-inferiority boundary
 - ✓ The results may be considered inconclusive.
- 2) The open arm of the LACC trial had the best ever reported outcomes.
 - ✓ The 4.5-year DFS rate in the open arm of the LACC trial was 96.5%, compared to 86% in the MIS arm.
 - ✓ The other studies have nearly all reported 4.5–5–year DFS/PFS rates of approximately 90%.
- 3) Preoperative MRI was not required
 - \checkmark Which may have affected the inclusion of tumors larger than 4 cm.
- 4) No of the external validity




M.M. Leitao, et al. Gynecologic Oncology 166 (2022) 417-424

2. Debates in the LACC trial

- 4) Tumor contamination
 - Effect of the insufflation gas (CO2)
 - Routine use of uterine manipulato

SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer

Chiva L et al. 2020, In J Gynecol Cancer



2. Debates in the LACC trial

- 4) Tumor contamination
 - Effect of the insufflation gas (CO2)
 - Routine use of uterine manipulator

Patterns of recurrence and survival after abdominal versus laparoscopic/robotic radical hysterectomy in patients with early cervical cancer

1 Right

paracolic gutter

3

LRH-IC

Patients

Recurrence

colpotomic

(months) Surgical and

Sites of recurrence

Table 5 Clinicopathologic characteri

| | | | | | | al | | | | | | | |
|---------------|-------------------------|------------------------------|--|-----------------------------|---------------------------------|----------------|----|----------|-----------|-----------------|----------|-------|-----|
| | VS. | LRH/F (N=49 | RRH-IC)) | | | ulative surviv | | | | | | | |
| eristics of J | patients wi | th <mark>intraperitor</mark> | neal recurrence | | | ∃ 0.4 - | | | | 8.7 vs =0.02 | | % | |
| | 2 | 3 | 4 | 5 | 6 | 0.2 - | | | (P | | | | |
| par | ight acolic ıtter | Subhepatic area | Splenic hilar surface (Splenectomy) | Bowel serosa (Colectomy) | Peritoneal & omental mass | 0.0 - | 0 | 20 | 40 | 60 | 1 80 | 100 | |
| 5 | 4 | 10 | 12 | 16 | 9 | | | | Time (n | nonths) | | | |
| LR | H-IC | LRH-IC | LRH-IC | RRH-IC | LRH-VC | | Ko | ng T-W e | t al. 20′ | l6 J Obs | stet Gyn | aecol | Res |

0.8

LRH-VC LRH/RRH-IC LRH-VC-censored LRH/RRH-IC-censored

2. Debates in the LACC trial


- 5) "Con" papers
 - ✓ large population-based studies

Survival of patients with early-stage cervical cancer after abdominal or laparoscopic radical hysterectomy: a nationwide cohort study and literature review



1237 cervical cancer patients identified, diagnosed between 2010 -

2017 with: FIGO stage IA2 with




Hans H.B. Wenzel et al. European Journal of Cancer 133 (2020) 14e21

2. Debates in the LACC trial

- 5) "Con" papers
 - ✓ large population-based studies

No survival difference between robotic and open radical hysterectomy for women with early-stage cervical cancer: results from a nationwide population-based cohort study

Swedish cancer registry




Emilia A. et al. European Journal of Cancer 116 (2019) 169e177

Ongoing RCT

계명대학교 동산병원 KEIMYUNG UNIVERSITY DONGSAN HOSPITAL



ROCC/GOG3043 trial(NCT048331580)



- Sample size ; 840 patients
- Primary endpoint ; 3-yr DFS
- From March 2022 to August 2029
- No use of uterine manipulator
- Preop MRI






Visits:

Assessment:

1 month after surgery^{1,2} 6 months after surgery 1 year after surgery^{2,3} 2 years after surgery² 3 years after surgery' 5 years after surgery

treatment. ' Only evaluation of recurrence.

RACC trial (NCT03719547)



Adjuvant treatment as per national guidelines and indication


Study specific follow-up

lymphoedema, recurrence and HRQoL . Including postoperative complications. Including collection of blood for biobank if participation in the translational part of the RACC trial. Including possible adjuvant Follow-up according to national guidelines

- Sample size ; 800 patients
- Primary endpoint
 ; 5-yr Recurrence-free survival
- From May 2019 to Feb 2027
- No use of uterine manipulator







- This study aimed to compare the surgical outcomes and cost of robotic single-site radical hysterectomy (RSSRH) versus robotic multiport radical hysterectomy (RMPRH) with pelvic lymph node dissection in early stage cervical cancer.
- Sixty-two patients with early stage cervical cancer were recruited between November 2011 and July 2017 and underwent RSSRH (20 patients) and RMPRH (42 patients) for early stage cervical cancer using the da Vinci Si Surgical System.



Jang TK, Chung H, Kwon SH, Shin SJ, Cho CH. Int J Med Robot. 2021;17(4): e2255.

| Parameter | RSSRH (N = 20) | RMPRH (N = 42) | p |
|--|-----------------|-----------------|---------|
| <intraoperative></intraoperative> | | | |
| Estimated blood loss (ml) | 215.0 (50-500) | 221.4 (100-500) | 0.911 |
| Blood transfusion | 1 (4.2) | 3 (7.1) | 0.759 |
| Conversion to laparoscopy or laparotomy | 0 | 0 | - |
| Major intraoperative complication ^a | 0 | 0 | - |
| Operation time (min), median | | | |
| Docking time | 6.5 (4-14) | 10.0 (3-20) | 0.107 |
| Console time | 102.5 (51-158) | 117.5 (63–255) | 0.112 |
| Closure time | 25.0 (13-45) | 25.0 (10-50) | 0.471 |
| Total | 186.0 (128–259) | 194.0 (138-329) | 0.1 |
| <postoperative></postoperative> | | | |
| Major postoperative complications ^b | 1 (5.0) | 2 (4.8) | 0.967 |
| Haemoglobin drop (g/dl) | 1.3 (0.3–2.5) | 1.5 (0.2-4.0) | 0.224 |
| Lymph node retrieval | 9.5 (4-17) | 18.0 (3–36) | < 0.001 |
| Postoperative hospital discharge (days) | 6.0 (4-14) | 11.0 (4-27) | < 0.001 |
| Total hospital charge (won) | 6323 422 | 9158 426 | <0.001 |

Jang TK, Chung H, Kwon SH, Shin SJ, Cho CH. Int J Med Robot. 2021;17(4): e2255.



| Parameter | RSSRH ($N = 20$) | RMPRH ($N = 42$) | р |
|-------------------------------|--------------------|--------------------|-------|
| Postoperative biopsy | | | |
| Tumour size (mm), range | 16.2 (8-25) | 18.5 (6-27) | 0.263 |
| Lymphovascular space invasion | 7 (35.0) | 10 (23.8) | 0.377 |
| Lymph node metastasis | 0 (0.0) | 2 (4.8) | 0.556 |
| Parametrium metastasis | 1 (5.0) | 4 (9.5) | 0.663 |
| Adjuvant therapy | 7 (35.0) | 13 (31.0) | 0.75 |
| Radiation | 1 (5.0) | 1 (2.4) | |
| Chemoradiation | 6 (30.0) | 12 (28.6) | |
| Recurrence | 1 (5.0) | 2 (4.8) | 0.967 |
| Alive | 19 (95.0) | 40 (95.2) | 0.967 |
| Death | 1 (5.0) | 2 (4.8) | |
| Due to disease | 1 (5.0) | 1 (2.4) | |
| Related to disease | 0 (0.0) | 1 (2.4) | |

Note: Data are presented as number (%) or median (range).

Abbreviations: RMPRH: robotic multiport radical hysterectomy; RSSRH: robotic single-site radical hysterectomy.

Jang TK, Chung H, Kwon SH, Shin SJ, Cho CH. Int J Med Robot. 2021;17(4): e2255.



- RSSRH procedure was safer, more feasible, cost-effective and had better short-term perioperative outcomes than RMPRH.
- This technique could also be used to train residents and surgical fellows in well-selected cases.
- Long- term rates of complications and postoperative radiotherapy or chemotherapy associated with the procedures need to be explored.
- Randomized trials are needed to determine whether robotic single- site techniques may offer clinical advantages over conventional procedures.



Jang TK, Chung H, Kwon SH, Shin SJ, Cho CH. Int J Med Robot. 2021;17(4): e2255





Article

Robotic Single-Site Radical Hysterectomy for Early Cervical Cancer: A Single Center Experience of 5 Years

Changho Song⁺, Tae-Kyu Jang⁺, Soomin Kong, Heeju Kang, Sang-Hoon Kwon and Chi-Heum Cho^{*}

- A 5-year experience of robotic single-site radical hysterectomy (RSRH) focused on the surgical and oncologic outcomes
- This retrospective study included 44 cases of RSRH in patients with early cervical cancer, which were performed at Keimyung university Dongsan hospital, Daegu, Korea from 2015 to 2020.



- The indications for RSRH were patients with FIGO stage Ia2, Ib1, and Ib2 without a risk of massive adhesion owing to previous operations.
- The robot platform used in this study was the da Vinci Si or X (Intuitive surgical, Sunnyvale, CA, USA)



Table 1. Patient characteristics.

| Variables | Total (n=44) | |
|--------------------------------|------------------|--|
| Age {median (range), years} | 45 (30 - 65) | |
| Age > 60 (n, %) | 5 (11.4) | |
| BMI (mean ± SD, kg/m²) | 23.96 ± 4.04 | |
| BMI < 18.5 (n, %) | 4 (9.1) | |
| BMI 18 to < 25 (n, %) | 26 (59.1) | |
| BMI 25 to < 30 (n, %) | 10 (22.7) | |
| BMI ≥ 30 (n, %) | 4 (9.1) | |
| Parity | | |
| Multiparous (n, %) | 38 (86.4) | |
| Nulliparous (n, %) | 6 (13.6) | |
| Pre-operative FIGO stage | | |
| Stage Ia1 (n, %) | 0 (0.0) | |
| Stage 1a2 (n, %) | 5 (11.4) | |
| Stage 1b1 (n, %) | 27 (61.3) | |
| Stage 1b2 (n, %) | 12 (27.3) | |
| Stage 1b3 (n, %) | 0 (0.0) | |
| Histologic type | | |
| Squamous cell carcinoma (n, %) | 33 (74.0) | |
| Adenocarcinoma (n, %) | 11 (26.0) | |

SD, standard deviation; BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics.



Table 2. Surgical outcome.

| Variables | Total (n=44) | |
|--|--------------------|--|
| Total operation time (mean ± SD) | 156.07 ± 31.77 min | |
| Setting time (mean ± SD) | 23.49 ± 6.67 min | |
| Preparation time (mean ± SD) | 8.42 ± 4.58 min | |
| Docking time (mean ± SD) | 6.05 ± 2.85 min | |
| Console time (mean ± SD) | 95.81 ± 24.95 min | |
| Closure time (mean ± SD) | 22.30 ± 7.55 min | |
| Conversion to laparoscopy or laparotomy (n, %) | 0 (0) | |
| Blood transfusion (n, %) | 0 (0) | |
| Retrieved lymph nodes (median [range]) | 9 (2 – 20) | |
| Estimated blood loss (mean ± SD) | 189.77 ± 132.32 ml | |
| Complication | | |
| Minor (n, %)ª | 10 (22.7) | |
| Major (n, %) ^b | 2 (4.5) | |
| Days of hospital stay (median [range]) | 5 (3 – 60) days | |

*Minor complications includes 3 cases of excessive drainage, 4 cases of voiding difficulties, 2 cases of abdominal pain, and 1 case of free fluid collection. bMajor complication includes 1 case of vaginal cuff disruption and 1 case of rectal perforation. SD, standard deviation.




Table 4. Oncologic outcomes.


| Variables | Total (n=44) |
|---------------------------------------|--------------------------|
| Tumor size | |
| < 2cm | 32 (72.7) |
| ≥ 2 cm, < 3cm | 9 (20.5) |
| \geq 3 cm, < 4cm | 3 (6.8) |
| Tumor involvement of parametrium | |
| no | 41 (93.2) |
| present | 3 (6.8) |
| Tumor involvement of resection margin | |
| no | 42 (95.5) |
| present | 2 (4.5) |
| Tumor involvement of lymph node | |
| no | 34 (77.3) |
| present | 10 (22.7) |
| Adjuvant therapy (n, %) | 15 (34.1) |
| RTx only (n, %) | 2 (4.5) |
| CCRT (n, %) | 13 (29.5) |
| Recurrence (n, %) | 4 (9.1) |
| Recurred site | |
| Local recurrence (n) | 2 |
| Distant metastasis (n) | 2 |
| Time to recur (median, range) | 16.9 (6.9 – 36.2) months |
| Cancer related death (n) | 1 |

CCRT, chemo-radiotherapy; RTx, Radiotherapy.

J. Pers. Med. 2023, 13, x. https://doi.org/10.3390/xxxxx







Patients with stages Ia2 and Ib1 cervical cancer showed better disease - free survival (DFS) than those with stage Ib2 cervical cancer following robotic single site radical hysterectomy.


J. Pers. Med. 2023, 13, x. https://doi.org/10.3390/xxxxx



- A recent randomized control trial reported that the DFS and overall survival of patients with cervical cancer who underwent MIS in radical hysterectomy is inferior to that in open abdominal radical hysterectomy
- The survival analysis in our study consistently demonstrated that patients with stage under Ib1 showed significantly favorable DFS than those in stage Ib2 and that stage was the only factor that influenced DFS.
- we presented the surgical and oncologic outcomes of RSRH in early stage cervical cancer treatment. RSRH may be considered as a feasible treatment option for early stage cervical cancer patients.









Published online: March 25, 2022 DOI: https://doi.org/10.36637/grs.2022.00094

Case report of lighted ureteral stent insertion with robotic singlesite radical hysterectomy in early cervical cancer treatment

Changho Song, Seungmee Lee, Hyewon Chung, Tae-Kyu Jang, Sang-Hoon Kwon, Chi-Heum Cho

Department of Obstetrics and Gynecology, School of Medicine, Keimyung University, Daegu, Korea

Correspondening author: Chi-Heum Cho Department of Obstetrics and Gynecology, School of Medicine, Keimyung University, 1095 Dalgubeol-daero, Dalseo-gu, Daegu 42601, Korea E-mail: c0035@dsmc.or.kr

Received February 10, 2022 Revised March 21, 2022 Accepted March 21, 2022

Copyright © 2022 Society of Korean Robotic Gynecologic Surgery

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.





Lighted ureteral stent insertion with robot assisted single-site radical hysterectomy in early cervical cancer treatment

Changho song, Seungmee Lee, Hyewon Chung, Tae-Kyu Jang, Sang-Hoon Kwon, Chi-Heum Cho

Departments of Obstetrics and Gynecology, Keimyung University School of Medicine, Daegu, Korea



Conclusion

- ✓ Since the introduction of the single-site robot in 2014, RSS surgery has been performed in the gynecological cancer area, and it has been confirmed that the long-term survival rate and the surgical outcome are good in the well-designed surgical indications so far.
- ✓ It shows good results in the area of gynecological cancer attempted in appropriate indications.
- ✓ The ultimate goal of robotic surgery is to make all surgeries possible with a single incision.



Thank you for your attention.

